 For subjects who have confirmed CR, PR, or SD non-progression after 4 cycles of induction therapy, maintenance therapy with pembrolizumab 2 mgkg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from Cycle 1, Day 1 C1D1. Subjects who complete 24 months of treatment with pembrolizumab may be eligible for up to one year of additional study treatment if they progress after stopping study treatment provided they continue to meet inclusion criteria requirements. 